Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as docetaxel
SB-715992 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Subjects receiving carboplatin and SB-715992 | EXPERIMENTAL | Subjects will receive carboplatin on Day 1 as an intravenous (IV) infusion over 30 minutes followed by 1-hour IV infusion of SB-715992 once every 21 days. |
| Name | Type | Description |
|---|---|---|
| SB-715992 | DRUG | SB-715992 will be available either as 5 milliliter (mL) vial containing 4 milligram (mg) of SB-715992 or 4 mL vial containing 5 mg of SB-715992 at a concentration of 1 mg/mL OR a 10 mL vial that contains 10 mg of SB-715992 in a 10 mL solution at a concentration of 1 mg/mL. |
| carboplatin | DRUG | Carboplatin will be available as sterile, lyophilized white powder available in single-dose vials containing 50 mg, 150 mg, and 450 mg of carboplatin for administration by IV infusion. Each vial will be reconstituted with either Sterile Water for Injection, USP, 5% Dextrose in Water (D 5 W), or 0.9% Sodium Chloride Injection, USP. |
| docetaxel | DRUG | - |
Inclusion criteria: * Histologically or cytologically confirmed diagnosis of an advanced solid tumor malignancy that is not responsive to standard therapies or for which there is no standard therapy. * ECOG (Eastern Cooperative Oncology Group) Performance Status of 0-2. Exclusion criteria: * Fema...
SB-715992 is an investigational small molecule being studied for the treatment of solid tumor cancer and solid tumours. It is in Phase 1 clinical development, with completed trials evaluating it in combination with other agents in patients with advanced solid tumors.
SB-715992 is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The drug is currently in Phase 1 clinical development for oncology indications.
SB-715992 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities, and remains under study for the treatment of solid tumor cancers.
SB-715992 has been studied in two completed Phase 1 clinical trials. NCT00136578 evaluated ispinesib in combination with carboplatin in patients with solid tumors, and NCT00169520 studied SB-715992 in combination with docetaxel in patients with solid tumor cancer.
SB-715992 is also known as ispinesib. In clinical trials, the drug has been referred to by both names, with NCT00136578 titled 'Ispinesib In Combination With Carboplatin' and NCT00169520 titled 'SB-715992 In Combination With Docetaxel'.